Scholarlink

Background <p>Meningiomas are the most common primary intracranial tumors in adults, accounting for more than one-third of brain neoplasms. Most are slow-growing, but higher-grade subtypes (WHO grades II–III) often recur, invade surrounding structures, and remain difficult to treat. Surgery, with or without radiotherapy, is still the standard of care, yet outcomes are limited by resistance and the lack of effective systemic therapies.</p> Main body <p>Recent advances in molecular research have revealed diverse mechanisms that drive therapeutic resistance. Genetic and epigenetic alterations such as neurofibromin 2 (NF2) loss and chromatin remodeling defects contribute to radioresistance and treatment failure. The tumor microenvironment supports survival through hypoxia, angiogenesis, immune evasion, and neuronal interactions, while metabolic reprogramming enables adaptation to therapy. These discoveries are guiding new approaches, including targeted inhibitors, immune checkpoint blockade, epigenetic and metabolic therapies, and drug repurposing strategies such as statins, metformin, and mechanistic target of rapamycin (mTOR) inhibitors. At the same time, biomarker development—spanning molecular profiling, liquid biopsy, and functional imaging—is refining risk stratification and patient selection.</p> Conclusion <p>The management of meningiomas is shifting toward mechanism-based, personalized strategies. Combining molecular insights with targeted therapies, immunomodulation, and repurposed drugs has the potential to overcome resistance and improve outcomes. Continued biomarker development and well-designed clinical trials will be crucial for translating these advances into practice.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Targeting meningiomas: advances in molecular pathways, drug repurposing, and precision therapy

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月23日

查看全文
  • Mohammed A. Abdel-Rasol,
  • Wael M. El-Sayed

摘要

Background

Meningiomas are the most common primary intracranial tumors in adults, accounting for more than one-third of brain neoplasms. Most are slow-growing, but higher-grade subtypes (WHO grades II–III) often recur, invade surrounding structures, and remain difficult to treat. Surgery, with or without radiotherapy, is still the standard of care, yet outcomes are limited by resistance and the lack of effective systemic therapies.

Main body

Recent advances in molecular research have revealed diverse mechanisms that drive therapeutic resistance. Genetic and epigenetic alterations such as neurofibromin 2 (NF2) loss and chromatin remodeling defects contribute to radioresistance and treatment failure. The tumor microenvironment supports survival through hypoxia, angiogenesis, immune evasion, and neuronal interactions, while metabolic reprogramming enables adaptation to therapy. These discoveries are guiding new approaches, including targeted inhibitors, immune checkpoint blockade, epigenetic and metabolic therapies, and drug repurposing strategies such as statins, metformin, and mechanistic target of rapamycin (mTOR) inhibitors. At the same time, biomarker development—spanning molecular profiling, liquid biopsy, and functional imaging—is refining risk stratification and patient selection.

Conclusion

The management of meningiomas is shifting toward mechanism-based, personalized strategies. Combining molecular insights with targeted therapies, immunomodulation, and repurposed drugs has the potential to overcome resistance and improve outcomes. Continued biomarker development and well-designed clinical trials will be crucial for translating these advances into practice.